Business Wire
11 Jun 2026, 17:33 UTC · 14w ago
Verdict
Headline leans bearish. We score ADMA −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
ADMA Biologics is facing a securities fraud lawsuit following allegations of channel stuffing.
More negative than 99% of claims this week
The company's stock price dropped 16% following the channel stuffing claims.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
More negative than 90% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is being sued for securities fraud following allegations of channel stuffing and a significant stock price drop.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
6h ago
+12.1%
Price is moving against the score
$9.51 vs $8.48 close before publication (Jun 10) · not market-adjusted
ADMA chart →